Vitamin B Derivative Reduces Risk for Further Skin CancerVitamin B Derivative Reduces Risk for Further Skin Cancer

An inexpensive and widely available vitamin D3 product, nicotinamide, has been shown to reduce significantly the development of further skin cancers. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: Available online 16 July 2019Source: Journal of Advanced ResearchAuthor(s): Laura Botta, Luigino Dal Maso, Stefano Guzzinati, Chiara Panato, Gemma Gatta, Annalisa Trama, Massimo Rugge, Giovanna Tagliabue, Claudia Casella, Bianca Caruso, Maria Michiara, Stefano Ferretti, Flavio Sensi, Rosario Tumino, Federica Toffolutti, Antonio Giampiero Russo, Anna Luisa Caiazzo, Lucia Mangone, Walter Mazzucco, Silvia IacovacciAbstractThe aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patien...
Source: Journal of Advanced Research - Category: Research Source Type: research
ConclusionsThis study brings out consequential information on factors linked with invaded or insufficient excision margins. Larger cohorts should evaluate the aesthetic outcomes in such a population.
Source: Journal of Cranio Maxillofacial Surgery - Category: ENT & OMF Source Type: research
In conclusion, both types of nanocarriers can be used for their potential treatment of SCC using PDT depending on the tumour localization in the skin.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Black people can get skin cancer, though it is less likely to affect them than people with lighter skin. For darker-skinned people, it usually occurs on lighter areas of the skin. Learn more here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
We report 2 elderly female patients with LPE who developed squamous cell carcinoma (SCC). Both underwent laparoscopic ischemic gastric preconditioning followed 2 weeks later by 3-field esophagectomy. Final pathological stages were carcinoma-in-situ and pT3N2, respectively. No adjuvant therapy was given. The patient with in-situ cancer has no evidence of recurrence at 24 months. The 2nd patient opted to follow up locally and died 8 months later. LPE should be closely monitored for malignant degeneration. Esophagectomy should be considered when malignancy is detected.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
We describe herein a patient with metastatic melanoma who developed epididymo‐orchitis followed by encephalitis while receiving pembrolizumab. The patient developed testicular pain and fever after his third dose of pembrolizumab; ultrasound evaluation demonstrated bilateral epididymo‐orchitis. He then developed headaches, fever, and altered mental status over the next week and was admitted to the hospital. Lumbar puncture revealed inflammatory changes consistent with meningoencephalitis; he did not improve with broad‐spectrum antibiotics, and an extensive workup for infectious etiologies, including cerebrospinal flui...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Melanoma and Cutaneous Malignancies Immune ‐ Related Adverse Events Source Type: research
Conclusion: SEMS effectively reduced dysphagia in inoperable esophageal cancer. Better survival rates were observed in females than males.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
AbstractTherapies for advanced non‐small cell lung cancer (NSCLC) continue to become more sophisticated. Chemotherapeutics are giving way to newer approaches such as immune checkpoint inhibitors and targeted therapies for greater efficacy and improved outcomes. Dabrafenib plus trametinib combination therapy was first approved for the treatment of metastatic melanoma harboring the BRAF V600‐mutation in 2014. In 2017, the U.S. Food and Drug Administration approved the combination for patients with NSCLC with the same mutation based on an ≈ 65% response rate and median progression‐free survival of 10–11 mont...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
Rutula Sonawane, Arunangshu Ghoshal, Anuja Damani, MaryAnn Muckaden, Jayita K DeodharIndian Journal of Palliative Care 2019 25(3):468-470 Rates of malignant melanoma have been increasing in frequency. Studies have shown that up to 46% of patients with melanoma will experience metastases to the central nervous system. Intramedullary spinal cord metastasis of malignant melanoma is rare. In advanced cancers, surgery might not be possible, and radiotherapy with corticotherapy is a viable option. In the following case, a 54-year-old male presented to the clinic with an intramedullary tumor in the D1 region. He was successf...
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
CONCLUSIONS: The level of serum microRNA-1290 in ESCC patients increased significantly, and its expression level could reflect the progress of ESCC, suggesting that serum microRNA-1290 might be a useful diagnostic and prognostic marker of ESCC. PMID: 31306104 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Skin | Skin Cancer | Vitamin B | Vitamins